AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) has been assigned an average recommendation of “Hold” from the nine analysts that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and four have given a buy recommendation to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $1.96.
A number of equities analysts recently weighed in on the stock. HC Wainwright downgraded shares of AVEO Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $1.00 target price on the stock. in a report on Friday, February 1st. ValuEngine downgraded shares of AVEO Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, January 31st. National Securities assumed coverage on shares of AVEO Pharmaceuticals in a report on Thursday, March 28th. They set a “sell” rating on the stock. BidaskClub upgraded shares of AVEO Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, January 15th. Finally, Robert W. Baird assumed coverage on shares of AVEO Pharmaceuticals in a report on Thursday, January 3rd. They set an “outperform” rating and a $3.00 target price on the stock.
In other news, major shareholder Equity Opportunities Fu Growth bought 4,347,827 shares of the stock in a transaction that occurred on Monday, April 8th. The shares were acquired at an average cost of $1.14 per share, for a total transaction of $4,956,522.78. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 4.40% of the stock is currently owned by insiders.
Shares of AVEO opened at $1.00 on Tuesday. The firm has a market cap of $140.39 million, a P/E ratio of -5.24 and a beta of 1.19. AVEO Pharmaceuticals has a 1-year low of $0.49 and a 1-year high of $3.59.
About AVEO Pharmaceuticals
AVEO Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC).
Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.